Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Zimmer Biomet stumbles as it lowers guidance

Monday, October 31, 2016 7:41
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Shares in Zimmer Biomet Holdings Inc (NYSE:ZBH) took a tumble after the medical devices maker disappointed with its outlook statement.

The maker of the eponymous Zimmer frame saw its shares fall 12.3% to US$107.44 in early deals, as it lowered earnings and sales guidance.

The company now expects full-year diluted earnings per share to fall within the range of US$1.50 to US$1.60, compared to previous guidance at the half-year stage of US$1.50 to US$1.75.

Revenue for the whole of 2016 is expected to be in the range of US$7.63bn to US$7.65bn, versus a previous guidance range of US$7.68bn to US$7.715bn.

Revenue growth, excluding the contribution from LDR Holding Corporation, on a constant currency adjusted pro forma basis, is now expected to be in a range of 1.65% to 1.90% for the full year 2016; previously, the company had estimated full-year revenue growth to be in a range of 2.5% to 3.0% on a similar basis.

The company, also famed for its hip and knee joint replacement products, reported a 615% year-on-year increase in net earnings to US$158.8mln. Adjusted earnings, which strips out exceptional items, was a somewhat more sedate 7.1% higher year-on-year at US$362.4mln.

Third quarter net sales rose 4% from a year earlier to US$1.83bn, helped by some mild foreign exchange tailwinds; stripping these out saw the rise reduce to 3.5%.

“Zimmer Biomet’s third quarter performance was highlighted by further acceleration of our global SET [Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma] category, as well as our continued strength in the Asia Pacific region,” said David Dvorak, who is both president and chief executive officer of Zimmer Biomet. 

“We believe that our comprehensive and expanding portfolio of musculoskeletal solutions positions us extremely well to address the evolving needs of customers in the dynamic healthcare environment in which they operate. Going forward, we will continue to focus on enhancements to our commercial and operational execution to more fully leverage our opportunities to improve the quality of life for patients and create value for our stockholders,” he added.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.